|
|
Session 10: New Biomarkers and High Throughput Screening Technology for Finding Hits, Leads and Preclinical Drug Candidates |
Session Chair: Dr. Xueheng Cheng, Sr. Group Leader, Biological Screening, Abbott Laboratories, USA
Co-Chair: Dr. Darius M. Dziuda, Assistant Professor, Data Mining and Statistics, Department of Mathematical Sciences, Central Connecticut State University, USA |
|
|
Title: An Efficient BAF/3-based Compound Profiling System for Kinase Inhibitor Identification and Development
Dr. Xiang-ju Gu, Group leader, Kinase Screening, Genomics Institute of the Novartis Research Foundation, USA |
|
Title: Drugs Effects and Drug Targets: Inhibition of Disulfide Reducing Enzymes and Antiproliferative Effects by Neuroleptics, Antimycotics, Antibiotics and other Drugs on Human Pathogenic Amoebas
Dr. R. N. Ondarza, Professor of Biochemistry, Faculty of Medicine, UNAM, Mexico, D.F. and Researcher on Medical Sciences, Center of Research on Infectious Diseases, INSP, Cuernavaca, Morelos, Mexico |
|
Title: Development of High Throughput And High Content Tools To Identify Novel Biomarkers And Drug Targets Related To The Assembly, Fusion And Elimination Of Lipid Droplets
Dr. Gerd Schmitz, Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Germany
|
|
Title: TRPV1 as a Target for Next Generation Analgesics
Dr. Louis S. Premkumar, Department of Pharmacology, Southern Illinois University School of Medicine Springfield, USA
|
|
Title: Drug Discovery and Development in Molecular Imaging
Dr. Yanming Wang, Departments of Chemistry and Radiology, Case Center for Imaging Research, Case Western Reserve University, USA
|
|
Title: Multivariate Biomarkers and The Informative Set of Genes
Dr. Darius M. Dziuda, Assistant Professor, Data Mining and Statistics, Department of Mathematical Sciences, Central Connecticut State University, USA
|
|
Title: Affinity Selection/mass Spectrometry, an Ultraefficient Affinity Screening Method and an Enabling Tool for Drug Discovery in the Post-genomics Era
Dr. Xueheng Cheng, Sr. Group Leader, Biological Screening, Abbott Laboratories, USA
|
|
